Discovery of remogliflozin etabonate: A potent and highly selective SGLT2 inhibitor.

ID: ALA4715919

Journal: Bioorg Med Chem

Title: Discovery of remogliflozin etabonate: A potent and highly selective SGLT2 inhibitor.

Authors: Shimizu K,Fujikura H,Fushimi N,Nishimura T,Tatani K,Katsuno K,Fujimori Y,Watanabe S,Hiratochi M,Nakabayashi T,Kamada N,Arakawa K,Hikawa H,Azumaya I,Isaji M

Abstract: We optimized the structure of an active metabolite (1) of WAY-123783, which was obtained from mouse urine after oral administration, to improve selectivity for SGLT2 and oral bioavailability. O-glucoside derivative 24 (remogliflozin etabonate) was subsequently identified as a potent, highly selective, and orally available SGLT2 inhibitor.

CiteXplore: 33581390

DOI: 10.1016/j.bmc.2021.116033

Patent ID: ┄